research
Focused Ultrasound Moved More Patients Toward Surgery
A 60-person Phase II study paired ultrasound with FOLFIRINOX and compared outcomes with a matched historical cohort.
Summary
A 60-person Phase II study paired ultrasound with FOLFIRINOX and compared outcomes with a matched historical cohort.
A Seoul National University Hospital Phase II trial enrolled 60 people with borderline-resectable or locally advanced pancreatic cancer; 56 completed focused ultrasound plus FOLFIRINOX. Compared with 56 propensity-matched historical controls, the combination group had higher tumor response, longer median survival, and more curative-intent surgeries. The nonrandomized comparison is encouraging but cannot establish the benefit as firmly as a randomized trial.
Why it matters
A 60-person Phase II study paired ultrasound with FOLFIRINOX and compared outcomes with a matched historical cohort.
Limits and context
- The nonrandomized comparison is encouraging but cannot establish the benefit as firmly as a randomized trial.
Key claims
A 60-person Phase II study paired ultrasound with FOLFIRINOX and compared outcomes with a matched historical cohort.
Qualification: The nonrandomized comparison is encouraging but cannot establish the benefit as firmly as a randomized trial.
Evidence: source-2026-07-23-009
Sources
- Focused Ultrasound Foundation via Newswise: Pancreatic cancer Phase II trialFocused Ultrasound Foundation via Newswise · official announcement
Corrections
No corrections have been recorded for this story.